Regen BioPharma and (OTCQB: RGBPP) believes it has taken full advantage of its recent prior discovery in developing small molecule drugs that activate NR2F6.
Dozens of Activating Compounds Identified |
| [16-October-2017] |
| SAN DIEGO, October 16, 2017 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) believes it has taken full advantage of its recent prior discovery in developing small molecule drugs that activate NR2F6. The Company recently reported that it identified key structural elements in small molecules that make them active and specific towards the NR2F6 target. Now, further chemical testing has revealed dozens of compounds which activate NR2F6 which contain the key motif discovered. The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient’s own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity. “Because our medicinal chemists were able to identify key structural elements in prior experiments, we can now add those elements to new compounds and screen other compounds that have that structure,” says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. “We did this and discovered dozens of new compounds that profoundly activated NR2F6. We are now selecting the best for further study.” “We are very excited at how well the medicinal chemistry program is working,” says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc. “We will file additional composition of matter patents around these structures shortly and we should be able to focus on just one or two of the best ones moving forward.” About Regen BioPharma Inc.: Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com. Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. CONTACT INFORMATION Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-702-1404 Phone +1-619-330-2328 Fax http://www.regenbiopharma.com david.koos@regenbiopharma.com
SOURCE Regen BioPharma Inc. | ||
Company Codes: Bloomberg:RGBP@US, RICS:RGBP, ISIN:US75886M1027, OTC-BB:RGBP, OTC-BB:RGBPP, OTC-QB:RGBP, OTC-QB:RGBPP, OtherOTC:RGBP, OtherOTC:RGBPP |
